Advert - Calendar - Radio

The Management and Members of the Kloma Hengme Association say their congratulations to Prof. Gabriel Teye Ayum

2015 ngmayem address by the konor of manya krobo nene sakite ii at the oklemekuku memorial park

Manya Krobo recognizes Krobo girls Headmistress at this years Ngmayem festival - Citation

Yokama: Young Women of Distinction Awards

The latest development in Manya Krobo - Senior high school Construction at Oborpah

Manya Krobo Inaugurates Development Committee and a website

Food For All Ghana Recovers Food To Feed Kinder Paradise Orphanage

Man Utd 4-2 Man City: Reds keep title hopes alive after outclassing rivals

Krobo Youth To Sue Two Individuals And Adom TV For Denigrating The Krobo Image

If I were the wife of a farmer...

DPSI reaches out to needy and abused children

Statement: Unlike Politicians, Media Must Not Fail West Africans - MFWA

The role of culture in sustaining peace and unity for national development

Traditional Council dismisses Krobo mountain sale rumours

Blows Over Krobo Mountains - Press Statement

Zenith Bank adjudged "Bank of the Year Ghana" at 2014 Banker Awards

Burkina will ask Morocco to extradite former president

I havent sacked ECG boss, Mahama

Curfew imposed on Nigerian town after explosion 'kills dozens'

ECOWAS launches 40 million Euro trade integration project

Revealed: Afriyie appointed as new Black Stars Management Committee Chairman

Atuabo gas powers Aboadze plant

Nigeria promises reliable and increased gas supply to Ghana

Ebola vaccine 'promising' say scientists after human trial

Open letter to Mahama: Reflections of a failing government

Zimbabwe's Zanu-PF blocks Joyce Mujuru leadership bid

Ferguson shooting: Protests spread across US

Invest in reliable data to enhance data collection - expert counsels

Nigerian senators initiate move to impeach Jonathan for corruption

Parliament suspended over cocaine row

Methodology by which we teach children in Ghana is archaic

Bawumia: Gov't blows $1bn Eurobond on BoG debt

5 Tricks to Burn More Calories and Keep Improving

Minority rubbishes new Power Ministry

President Nyantekyi promises Beach Soccer an Arena

Baby found in storm drain; woman charged with attempted murder

Telecoms chamber lauds move to remove taxes on smart phones

IMF backs Ghanas 2015 budget

No bright future with dim MPs!

Angry ECG workers demand reinstatement of sacked boss

Compaore leaves Ivory Coast for Morocco

Good Ways to Get Quality Protein

ECG Boss Sacked

5 million illegal immigrants in the U.S to escape deportation

Trades Ministry clarifies "war on interest rates" report

North Korea responds to UN with nuclear test threat

14 Ghanaians awarded Australian Masters scholarship

Burkina Faso's Lt Col Isaac Zida named prime minister

Govt imposes 17.5% Tax on petroleum products

Live Updates: Read in full abridged 2015 Budget Statement

Ghana Vs Togo: Black Stars probable lineup

Cocaine bust saga: NPP will politicize issue, expose NDC drug barons -- Agyarko

Adenta Presby YPG donates to nectar foundation - Lower Manya

Lawyer drags BoG to Supreme Court over cedi depreciation

Congestion at Mfantsipim SHS; students sleep on trunks

The Ghanaian Economy General Assessment by Citizen

Jerusalem synagogue: Palestinians kill Israeli worshippers

Overwhelming debts: Govt looks elsewhere to feed school kids

11 ways to snack smarter

Ecobank Emerges Most Profitable

MP pledges to restore health boat - Upper Manya

2015 Budget must deal with ailing economy - Majority, Minority leaders appeal

Abdul-Rahman Kassig: US hostage 'killed by IS'

The water story: breaking the myth of eight glasses per day

Rhythms of Thoughts: Dealing with the Shabab syndrome

Encouraging children to involve in sports

Donation Made to a brilliant student

Doing business in Manya Krobo

Community cleanup

Great things to know about Manya Krobo

5th Anniversary of Enstoolment as Manoyam Matse

Burkina Faso: Transitional framework agreed on

New Hospital Structure Under Construction

MANYA KROBO
The Land Of Endless Possibilities....

Home » News » International News » Ebola vaccine 'promising' say scientists after human trial

  • Print Friendly and PDF

Ebola vaccine 'promising' say scientists after human trial

Published On: 27 Nov 2014

Ebola vaccine 'promising' say scientists after human trial

Ebola vaccine 'promising' say scientists after hum



The first human trial of an experimental vaccine against Ebola suggests that it is safe and may help the immune system to combat the virus.

Twenty volunteers were immunised in the United States. Scientists at the US National Institutes of Health (NIH) described the results as "promising".

The research is published in the New England Journal of Medicine (NEJM).

None of those immunised suffered major side-effects and all produced antibodies.

Dr Anthony Fauci of the NIH told the BBC: "On safety and on the ability to produce an appropriate immune response we can call this trial an unqualified success, even though it was an early Phase One trial."

The volunteers were divided into two groups, receiving either a low or high dose. The antibody response was stronger among those receiving the higher dose.

The investigators found that seven of the high dose and two of the lose dose volunteers produced T-cell immune responses, which may be important in protection against Ebola viruses.

The vaccine uses a chimpanzee cold virus which has been genetically engineered to carry a non-infectious Ebola protein on its surface.

A health worker in Conakry, Guinea, wearing protective clothing

 A health worker in Conakry, Guinea, wearing protective clothing to treat victims

There are four trials underway of this experimental vaccine.

The US vaccine is bivalent - aimed at giving protection against the Sudan and Zaire strains of Ebola. It is the latter which is responsible for the current outbreak.

Trials of a monovalent vaccine - against the Zaire strain - are also underway in Oxford, Mali and Switzerland.

If these also yield positive results then the monovalent vaccine will be offered to thousands of health workers in west Africa.

Dr Fauci said: "It will be this large Phase Two / Three trial in west Africa which will show whether the vaccine works and is really safe."

He added: "If the outbreak is still is still going on six months from now and the vaccine at that point is shown to be effective, it could have a very positive impact on the current epidemic."

But he said the long-term aim was to produce a vaccine which would protect against future outbreaks.

If the vaccine does work, it is unclear how long the protection would last.

Indemnity agreement

These kinds of questions are usually settled during the early stages of human trials.

But such is the pressing humanitarian need for something which protects against Ebola, the whole trial process is being accelerated at unprecedented speed.

In an editorial in the NEJM Dr Daniel Bausch said that while the trial left many questions unanswered, an Ebola vaccine was "one step closer".

The experimental vaccine is being manufactured by the British drugs giant GlaxoSmithKline (GSK).

The company says it can produce one million doses a month by the end of 2015.

This will require a significant financial outlay. It is asking for an indemnity agreement in case problems such as unforeseen side effects were to emerge in the future.

GSK's chief executive Sir Andrew Witty told the BBC: "We are not waiting for that to be settled [but] it is obvious there are some risks that companies should not be expected to carry on their own."

Twenty volunteers were immunised in the United States. Scientists at the US National Institutes of Health (NIH) described the results as "promising".

The research is published in the New England Journal of Medicine (NEJM).

None of those immunised suffered major side-effects and all produced antibodies.

Dr Anthony Fauci of the NIH told the BBC: "On safety and on the ability to produce an appropriate immune response we can call this trial an unqualified success, even though it was an early Phase One trial."

The volunteers were divided into two groups, receiving either a low or high dose. The antibody response was stronger among those receiving the higher dose.

The investigators found that seven of the high dose and two of the lose dose volunteers produced T-cell immune responses, which may be important in protection against Ebola viruses.

The vaccine uses a chimpanzee cold virus which has been genetically engineered to carry a non-infectious Ebola protein on its surface.

 A health worker in Conakry, Guinea, wearing protective clothing to treat victims

There are four trials underway of this experimental vaccine.

The US vaccine is bivalent - aimed at giving protection against the Sudan and Zaire strains of Ebola. It is the latter which is responsible for the current outbreak.

Trials of a monovalent vaccine - against the Zaire strain - are also underway in Oxford, Mali and Switzerland.

If these also yield positive results then the monovalent vaccine will be offered to thousands of health workers in west Africa.

Dr Fauci said: "It will be this large Phase Two / Three trial in west Africa which will show whether the vaccine works and is really safe."

He added: "If the outbreak is still is still going on six months from now and the vaccine at that point is shown to be effective, it could have a very positive impact on the current epidemic."

But he said the long-term aim was to produce a vaccine which would protect against future outbreaks.

If the vaccine does work, it is unclear how long the protection would last.

Indemnity agreement

These kinds of questions are usually settled during the early stages of human trials.

But such is the pressing humanitarian need for something which protects against Ebola, the whole trial process is being accelerated at unprecedented speed.

In an editorial in the NEJM Dr Daniel Bausch said that while the trial left many questions unanswered, an Ebola vaccine was "one step closer".

The experimental vaccine is being manufactured by the British drugs giant GlaxoSmithKline (GSK).

The company says it can produce one million doses a month by the end of 2015.

This will require a significant financial outlay. It is asking for an indemnity agreement in case problems such as unforeseen side effects were to emerge in the future.

GSK's chief executive Sir Andrew Witty told the BBC: "We are not waiting for that to be settled [but] it is obvious there are some risks that companies should not be expected to carry on their own."


Do you have an article for publication? Please email it to editor@manyakrobo.com.



rolex replica watches uk replica cartier for men uk rolex oyster perpetual Replica uk replica cartier for men rolex replica watches uk for men top bell ross replica omega replica uk rolex replica watches uk to you replica cartier for men iwc replica watches for man cheap bell ross replica watches for men replica longines watches swiss iwc replica watches omega replica watches for lady replica cartier watches for sale uk rolex replica watch omega replica watches Tag Heuer copy iwc replica watches for lady replica longines watches uk omega replica watches swiss bell ross replica watches uk omega copy watches latest iwc copy watches Replica Rolex Watches rolex replica watch rolex replica rolex replica watches rolex replica watches uk Best Copy Cartier Watches best iwc replica fake longines for sale top omega replica breitling replica watches Replica Panerai Watches Uk For Men iwc replica watches for sale quality bvlgari replica Newest Replica U-boat omega seamaster 007 orange replica rolex watches uk for sale best fake chopard watches fake iwc watches for sale Rolex Gmt Replica rolex replica rolex replica watches rolex replica watches uk Omega Seamaster Quantum Of Solace omega replica watch cheap omega replica Omega Seamaster White Dial omega replica watch omega replica watches for sale swiss omega replica cheap omega replica Swiss Iwc Replica iwc replica watch iwc replica watches for sale swiss iwc replica cheap iwc replica